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Acute HIV-1 infectionralizing antibody speciﬁcities that are elicited following infection or vaccination
by HIV-1 is an important objective of current HIV/AIDS vaccine research. We have shown previously that
transplantation of HIV-1 V3 epitopes into an HIV-2 envelope (Env) scaffold provides a sensitive and speciﬁc
means to detect and quantify HIV-1 V3 epitope speciﬁc neutralizing antibodies (Nabs) in human sera. Here,
we employ this HIV-2/HIV-1 V3 scaffolding strategy to study the kinetics of development and breadth of V3-
speciﬁc Nabs in longitudinal sera from individuals acutely infected with clade C or clade B HIV-1 and in
human subjects immunized with clade B HIV-1 immunogens. HIV-2/HIV-1 chimeras containing V3
sequences matched to virus type (HIV-2 or HIV-1), subtype (clade B or C), or strain (autologous or
heterologous) were used as test reagents. We found that by 3–8 weeks post infection, 12 of 14 clade C
subjects had a median IC50 V3-speciﬁc Nab titer of 1:700 against chimeric viruses containing a heterologous
clade C V3. By 5 months post-infection, all 14 subjects were positive for V3-speciﬁc Nabs with median titers
of 1:8000 against heterologous clade C V3 and 1:1300 against clade B V3. Two acutely infected clade B
patients developed heterologous clade B V3-speciﬁc Nabs at titers of 1:300 and 1:1800 by 13 weeks of
infection and 1:5000 and 1:11000 by 7 months of infection. Titers were not different against chimeras
containing autologous clade B V3 sequences. Each of 10 uninfected normal human volunteers who were
immunized with clade B HIV-1 Env immunogens, but none of ﬁve sham immunized control subjects,
developed V3-speciﬁc Nabs titers as high as 1:3000 (median 1:1300; range 1:700–1:3000). None of the HIV-
1 infected or vaccinated subjects had antibodies that neutralized primary HIV-1 virus strains. These results
indicate that high-titer, broadly reactive V3-speciﬁc antibodies are among the ﬁrst to be elicited during acute
and early HIV-1 infection and following vaccination but these antibodies lack neutralizing potency against
primary HIV-1 viruses, which effectively shield V3 from antibody binding to the functional Env trimer.
© 2009 Elsevier Inc. All rights reserved.IntroductionAntibody speciﬁcities of the early humoral immune response to
HIV-1 that contribute to virus containment are not fully understood.
Antibody seroconversion occurs approximately 3 to 6 weeks follow-
ing HIV-1 transmission and is characterized by the sequentials, University of Alabama at
ll rights reserved.appearance of plasma antibodies elicited against multiple viral
proteins (Fiebig et al., 2003; Tomaras et al., 2008). Recent work has
shown that the earliest antibody responses to HIV-1 are directed at
the immunodominant region of the envelope (Env) protein gp41 and
generally develop within 2 weeks after viral RNA (vRNA) is ﬁrst
detected in the plasma (Tomaras et al., 2008). Antibodies to Gag
proteins arise at approximately 18 days (p24, p55) and 33 days (p17)
following detection of plasma vRNA and antibodies targeting the
polymerase proteins p66 and p31 appear approximately 21 and
53 days after detectable vRNA, respectively (Fiebig et al., 2003;
415K.L. Davis et al. / Virology 387 (2009) 414–426Tomaras et al., 2008). The Env glycoprotein gp120 elicits antibodies
that can be identiﬁed in peptide and gp120 binding assays at
approximately 28 days following detectable vRNA (Tomaras et al.,
2008). The epitope speciﬁcities and breadth of reactivity of these
early anti-gp120 antibodies have been the subject of limited
investigation. A recent study mapped the earliest anti-gp120 binding
antibody responses to include the third variable region (V3) and
reported that antibodies speciﬁc for CD4-induced (CD4i) epitopes,
the CD4 binding site (CD4bs), and the membrane proximal external
region (MPER) of gp41 were not identiﬁed among early anti-Env
responses (Tomaras et al., 2008). Additionally, antibodies targeting
gp120 and gp41 during the ﬁrst 40 days following detection of
plasma vRNA did not exhibit neutralizing activity (Tomaras et al.,
2008). This is in agreement with previous reports that documented
the appearance of anti-gp120 binding antibodies prior to the
development of autologous Nabs in the plasmas of acutely infected
individuals (Aasa-Chapman et al., 2004; Moore et al., 1994).
Antibodies capable of neutralizing the autologous virus strain
develop later in infection, approximately 12–16 weeks following
transmission, and such neutralizing antibodies (Nabs) are invariably
strain speciﬁc (Frost et al., 2005; Gray et al., 2007; Richman et al.,
2003; Wei et al., 2003). Early autologous Nab responses to HIV-1
generally target variable epitopes that are exposed on the functional
Env trimer, namely V1, V2, and possibly V4, and drive the evolution
of virus escape mutations that allow HIV-1 to rapidly evade Nab
pressures (Frost et al., 2005; Honnen et al., 2007; McKeating et al.,
1993; Moore et al., 2008; Pinter, 2007; Richman et al., 2003; Rong et
al., 2007a,b; Wei et al., 2003). Only much later in infection, and only
in a subset of HIV-1 infected individuals, do antibodies capable of
mediating broad neutralization develop (Burton et al., 2004; Doria-
Rose et al., 2009; Pantophlet and Burton, 2006; Sather et al., 2009).
Recent studies have mapped these broad Nab responses to conserved
gp120 epitopes including but not limited to the CD4bs (Binley et al.,
2008; Dhillon et al., 2007; Li et al., 2007).
To identify what contributions V3-speciﬁc antibodies might make
to the early Nab response to HIV-1 during acute and early infection
and after immunization, we developed a novel assay for detecting
and quantifying V3-speciﬁc Nabs in polyclonal human or animal sera.Fig. 1. Description of HIV-2KR.X7 Env scaffold and HIV-2/HIV-1 V3 chimeras. (A) The parent
restriction sequences in the leader peptide (LP) region (XhoI and SnaBI), the C3 coding r
mutations at amino acid positions 204 (E204K), 360 (T360A), and 668 (Y668H) to yield the
membrane proximal external region. (B) V3 sequences for HIV-1MN, HIV-1YU2, HIV-1Ccon, H
cassette as described in Materials and methods to generate the chimeric proviruses.Our approach is based on the observation that, although the
structure and functional biology of the HIV-1 and HIV-2 Envs are
similar (Chen et al., 2005), the primary amino acid sequence varies
by approximately 60% between these two glycoproteins and thus
they are antigenically distinct at surface-accessible Nab epitopes
(Bottiger et al., 1990; Decker et al., 2005; Weiss et al., 1988). In a
previous study (Davis et al., 2009), we tested the hypothesis that
substitution of the V3 region of HIV-2 with that of HIV-1 would result
in a functional chimeric viral Env glycoprotein that could be
employed as a molecular probe to detect V3-speciﬁc Nabs in
polyclonal plasmas. We found such HIV-2/HIV-1 V3 chimeras to be
infectious, replication competent, and sensitive to selective pharma-
cological inhibitors of virus entry. These chimeras were resistant to
neutralization by HIV-1 monoclonal antibodies (mAbs) directed at
the CD4bs (b12), membrane proximal external region (MPER; 2F5),
and CD4-induced (CD4i) epitopes (E51, 17b, 48d, 21c, 4.12D, 19e,
ED47, and ED49), but notably, were exquisitely sensitive to
neutralization by HIV-1 V3-speciﬁc mAbs (447–52D and F425
B4e8) and HIV-1 V3-speciﬁc polyclonal antibodies in the plasma of
chronically infected individuals (Davis et al., 2009).
Here, we explore the kinetics of appearance of V3-speciﬁc
antibodies in a cohort of patients acutely infected with clade C or
clade B HIV-1 and in subjects immunized with two vaccine products
derived from clade B viruses. We explore the strain and subtype
speciﬁcity of these V3-speciﬁc antibody responses and their con-
tributions to autologous and heterologous virus neutralization. The
results indicate that V3-speciﬁc antibodies develop faster and reach
higher titers than do antibodies directed at CD4i, MPER, or CD4bs
epitopes, and they are comparable or higher in titer compared with
strain-speciﬁc Nab titers that typically develop in early infection (Gray
et al., 2007; Li et al., 2006; Moore et al., 2008; Richman et al., 2003;
Wei et al., 2003). However, despite the high titers and rapidity with
which V3 antibodies are elicited, they contribute little, if any,
neutralizing activity against autologous or heterologous primary
viruses because the V3 epitopes of these viruses are effectively
shielded from antibody access within the functional Env trimer. We
discuss the potential importance of V3 Nab constraints on Env
conformation and V3 accessibility in the native glycoprotein.al pHIV-2KR.P1 env backbone (Davis et al., 2009) was modiﬁed to include unique silent
egion (XmaI), and 3′ of the transmembrane (TM) region (XbaI) and nonsynonymous
ﬁnal scaffold vector pHIV-2KR.X7. V1/2, V3, V4 — variable regions 1/2, 3, and 4. MPER—
IV-1WEAU, HIV-1BORI_d6, and HIV-1BORI_d556 were incorporated into the pHIV-2KR.X7 env
Table 1
Neutralization titers of clade C sera against HIV-2, HIV-1, and HIV-2/HIV-1 V3 chimeras.
Serum WPI Reciprocal IC50
HIV-
2KR.X4
HIV-
2KR.X7
HIV-2KR.X7
Ccon V3
HIV-2KR.X7
YU2 V3
Autologousa Heterologous
(HIV-1DU151)
CAP008 3 b20 b20 845 53 b20 b20
10 b20 b20 32425 1655 b20 b20
19 b20 b20 N62500 4369 124 b20
⁎25 b20 b20 N62500 5487 132 b20
37 b20 b20 N62500 5122 401 b20
CAP030 5 b20 b20 675 71 NDb b20
⁎21 b20 b20 22880 3388 ND b20
29 b20 b20 24853 3355 ND b20
39 b20 b20 24471 4172 ND b20
46 b20 b20 27799 6539 ND b20
54 b20 b20 48207 11908 ND b20
58 b20 b20 30166 9259 ND 63
71 b20 b20 39159 10256 ND 269
CAP045 5 b20 b20 b20 b20 b20 b20
12 b20 b20 3609 436 56 b20
18 b20 b20 3931 878 135 b20
⁎26 b20 b20 2973 1472 261 b20
35 b20 b20 2159 2950 512 b20
43 b20 b20 3730 5519 5772 b20
CAP061 8 b20 b20 889 130 b20 b20
15 b20 b20 2511 170 b20 b20
⁎25 b20 b20 4278 214 b20 b20
33 b20 b20 7536 528 b20 b20
41 b20 b20 7690 198 b20 b20
51 b20 b20 6813 254 38 104
58 b20 b20 14675 407 74 100
62 b20 b20 15059 210 61 111
CAP063 4 b20 b20 142 116 b20 b20
11 b20 b20 5609 1603 b20 b20
⁎20 b20 b20 17352 3707 642 b20
29 b20 b20 19822 5454 5322 b20
37 b20 20 21429 10958 6599 b20
CAP084 3 b20 b20 419 34 b20 b20
10 b20 b20 1554 64 b20 b20
⁎19 b20 b20 13317 636 b20 b20
37 b20 b20 12193 1316 2360 b20
47 b20 b20 13284 1719 1846 b20
CAP085 5 b20 b20 1485 121 b20 b20
13 b20 b20 7673 182 40 b20
⁎21 b20 b20 4579 1157 163 b20
CAP088 5 b20 b20 591 62 b20 b20
13 b20 b20 5316 1476 b20 b20
⁎22 b20 b20 8141 1182 656 b20
30 b20 b20 21773 3285 1109 b20
54 b20 b20 19542 3533 1363 b20
CAP206 8 b20 b20 15107 691 b20 b20
15 b20 b20 28467 1360 96 b20
⁎22 b20 b20 28946 2795 650 b20
CAP210 5 b20 b20 b20 b20 b20 b20
12 b20 b20 20 b20 b20 b20
18 b20 b20 1243 b20 b20 b20
⁎26 b20 b20 3410 145 b20 b20
38 b20 b20 4006 177 b20 b20
CAP228 7 b20 b20 2940 772 b20 b20
14 b20 b20 11055 2884 51 b20
⁎22 b20 b20 5374 2959 261 b20
30 b20 b20 9705 3614 415 b20
37 b20 b20 13668 4259 410 b20
CAP239 5 b20 b20 737 363 b20 b20
11 b20 b20 6305 2626 b20 b20
⁎19 b20 b20 3125 1420 331 b20
29 b20 b20 5207 4832 708 b20
CAP244 8 b20 b20 1064 214 b20 b20
14 b20 b20 2666 938 b20 b20
⁎23 b20 b20 2809 618 88 b20
32 b20 b20 2872 403 140 b20
40 b20 b20 2781 321 274 b20
CAP255 8 b20 b20 598 54 b20 b20
15 b20 b20 4778 b20 410 b20
⁎23 b20 b20 8127 b20 3286 b20
Table 1 (continued)
Serum WPI Reciprocal IC50
HIV-
2KR.X4
HIV-
2KR.X7
HIV-2KR.X7
Ccon V3
HIV-2KR.X7
YU2 V3
Autologousa Heterologous
(HIV-1DU151)
31 b20 b20 12766 146 2668 b20
39 b20 b20 13547 601 2275 b20
a Autologous neutralization titers were obtained from Gray et al. (2007) for all sera.
b ND: not done as no cloned envelope was available from this individual.
⁎ Indicates sera that were included in the analysis presented in Fig. 2B.
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Development of infectious HIV-2/HIV-1 V3 chimeras
Previously, we described the construction and biological char-
acterization of a panel of HIV-2/HIV-1 V3 chimeras that detect V3
reactive antibodies in complex plasma with a high degree of
sensitivity and speciﬁcity (Davis et al., 2009). These chimeras included
the HIV-2KR.X7 backbone (Fig. 1A) substituted with the V3 region of
the HIV-1 strains HIV-1MN (Gurgo et al., 1988), HIV-1YU2 (Li et al.,
1992), HIV-1BORI_d6 (Keele et al., 2008;Wei et al., 2003) and HIV-1Ccon.
In the present study, we utilized all of these viruses plus two
additional HIV-2KR.X7HIV-1 V3 chimeras containing V3 loops from
patients infected with clade B HIV-1, HIV-1WEAU (Wei et al., 2003) and
HIV-1BORI_d556 (Wei et al., 2003). The parental virus HIV-2KR.X4,
containing the wildtype HIV-2 Env protein, and the modiﬁed HIV-2KR.
X7 Env scaffold, that contains the wildtype HIV-2KR V3 loop and three
additional amino acid changes in Env that were found to enhance the
infectivity of the HIV-2/HIV-1 V3 chimeras (Davis et al., 2009), were
included as control viruses in all studies. Fig. 1B summarizes the
composition of the HIV-2/HIV-1 V3 chimeras and control viruses.
Kinetics of appearance and breadth of V3 reactive antibodies during
natural infection with clade C HIV-1
We assessed the kinetics of appearance of the V3-speciﬁc Nab
responses in longitudinal serum samples from 14 subjects acutely
infected with subtype C HIV-1 (CAPRISA cohort) using the HIV-
2KR.X7HIV-1 V3 chimeras and control viruses (Table 1 and Fig. 2A). All
subjects produced V3-speciﬁc antibodies capable of neutralizing the
clade-matched V3 chimera, HIV-2KR.X7Ccon V3, within the ﬁrst
12 weeks of infection. In 12 of 14 individuals, high-titer V3-speciﬁc
antibodies were detectable in serum samples collected at enrollment
into the study, which was estimated to be approximately 5 weeks
(median, range of 3 to 8weeks) post infection (wpi) (Gray et al., 2007).
Enrollment sera neutralized the HIV-2KR.X7Ccon V3 chimera at a
median reciprocal IC50 serum dilution of 706 (range, b20 to 15,107)
and increased in titer as infection progressed to as high as N62,500
(median=13,608; range 2781 to N62,500). Additionally, the V3
neutralizing activities observed in these patients exhibited cross-
clade reactivity as demonstrated byamedian enrollment neutralization
titer against the HIV-2KR.X7YU2 V3 chimera of 94 (range, b20 to 772),
which increased over time to as high as 10,958 (median=3164; range
177 to 10,958). HIV-2KR.X4 and HIV-2KR.X7 served as controls for these
experiments. Both viruses were resistant to neutralization by all sera,
suggesting that neutralization of the HIV-2KR.X7HIV-1 V3 chimeras was
restricted to V3 epitopes (Table 1), which we conﬁrmed by Fc-V3C
fusion protein competition studies (Fig. 3).
The natural history of HIV-1 infection and sequential development
of V3-speciﬁc Nabs in subject CAP008 highlight these observations
(Fig. 2). Serum from CAP008 drawn at approximately 3 wpi
neutralized the HIV-2KR.X7Ccon V3 chimera at a reciprocal IC50 plasma
dilution of 845. Subsequent serum samples from CAP008 neutralized
the HIV-2KR.X7Ccon V3 chimera with increasing potency
(IC50=32,425 at week 10) reaching exceptionally high titers by
week 19 post infection and beyond (N62,500 at weeks 19, 25, and 37).
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reciprocal IC50 plasma dilutions of 53 (week 3), 1655 (week 10),
4369 (week 19), 5487 (week 25), and 5122 (week 37). These
observations were typical of most of the subjects participating in
this natural history study and demonstrate both the rapid kinetics of
appearance and high titers of V3 responses elicited by natural
infection. In addition, they highlight a certain degree of clade
speciﬁcity in what otherwise would be considered broad neutralizing
activity (i.e., a Nab activity that neutralizes both clade C and clade B V3
chimeric viruses at titers exceeding 1:1000).
There were, however, exceptions to the pattern of neutralization
found in subject CAP008. For example, CAP210 barely mounted a
detectable V3-speciﬁc antibody response within the ﬁrst 12 weeks of
infection (Fig. 2A and Table 1); her serum at 12 wpi only weakly
neutralized the clade-matched chimera (reciprocal IC50 plasma dilu-
tion=20) and failed to neutralize the clade B (YU2) V3 chimera. At
subsequent time points, the CAP210 V3-speciﬁc antibody response
continued to increase in titer reaching a reciprocal IC50 titer of 4006 by
38wpi. These antibodies, however,were ofnarrowerbreadth than those
observed for other patients in this study as demonstrated by the slower
kinetics and much lower titer of the reactivity to the HIV-2KR.X7YU2 V3
chimera. Conversely, the breadth of the V3-speciﬁc antibody response
observed for CAP045 and CAP239 was such that maximum Nab titers
against the HIV-2KR.X7Ccon V3 chimera and the HIV-2KR.X7YU2 V3
chimera were equivalent (Fig. 2A and Table 1).
We next compared the V3-speciﬁc neutralizing titers of the
CAPRISA sera measured against the HIV-2/HIV-1 chimeras with
Nab titers measured against autologous and heterologous primary
HIV-1 Envs. The autologous Envs were cloned from the enrollment
plasma for each patient and used to pseudotype an Env-deﬁcient
HIV-1 backbone virus (Gray et al., 2007). Heterologous neutraliza-
tion titers for the sera were determined against the clade C isolate
HIV-1Du151. For these studies, we plotted the reciprocal IC50
neutralization titers for sera that were obtained at a median time
of 5 months post infection (range, 4.4 to 6.1) against the panel of
HIV-2KR.X7HIV-1 V3 chimeras and against autologous and hetero-
logous HIV-1.
As demonstrated in Fig. 2B, all individuals in the CAPRISA natural
infection cohort developed potent V3-speciﬁc Nab responses within
the ﬁrst 5 months of infection reaching a median reciprocal IC50
neutralization titer of 8127 (range, 2809 to N62,500) against the HIV-
2KR.X7Ccon V3 chimera. The cross-clade V3-speciﬁc reactivities were
more variable and exhibited a median titer of 1301 (range, b20 to
5487) against the HIV-2KR.X7YU2 V3 chimera at this time point.
Neutralization of viruses pseudotyped with the autologous primary
HIV-1 Env showed a median reciprocal IC50 serum dilution of 261
(range, b20 to 3286). This titer was signiﬁcantly lower than either of
the V3-speciﬁc Nab activities measured against the HIV-2KR.X7Ccon V3
or HIV-2KR.X7YU2 V3 chimeras (p=0.0162 and 0.0285, respectively).
These same sera demonstrated no detectable neutralization against a
heterologous clade C primary Env, despite the preponderance of high
titer V3-speciﬁc antibodies and detectable strain speciﬁc Nabs. These
results are consistent with a report by Gray et al. (2007) in which it
was shown that these same CAPRISA cohort sera obtained at 6 months
post infection displayed limited neutralizing activity against other
heterologous Envs. In our study, only two patients, CAP030 and
CAP061, developed detectable Nabs against heterologous HIV-1Du151
within the ﬁrst 58 weeks of infection, reaching maximum titers of 269
and 111, respectively (Table 1).
Epitope speciﬁcity of neutralization of HIV-2KR.X7HIV-1 V3 chimeras by
acute and early HIV-1+ sera
To conﬁrm the V3-speciﬁcity of neutralization detected by the
HIV-2KR.X7Ccon V3 chimera, we performed competition experiments
using linear peptides composed of the full-length autologous V3region or a fusion protein that presents the full-length Ccon V3 in
its disulﬁde-bound form. For these competition studies, sera were
incubated with peptide or fusion protein at 37°C 30 min prior to
the addition of HIV-2KR.X7Ccon V3 and transfer to the TZM-bl
reporter cells. Fig. 3 shows that sequence-matched, full-length V3
peptides were relatively inefﬁcient at removing the neutralizing
activity in the CAPRISA sera: in all cases, these peptides absorbed
only a fraction of the serum neutralizing activity detected by the
HIV-2KR.X7Ccon V3 chimera as evidenced by a rightward shift in the
neutralization curves. For example, serum from CAP084 drawn at
enrollment neutralized HIV-2KR.X7Ccon V3 at a reciprocal IC50
plasma dilution of 423 in the absence of competing peptide. Pre-
incubation of CAP084 serum with autologous V3 peptide resulted in
a reciprocal IC50 titer of 179 against the HIV-2KR.X7Ccon V3 chimera,
a modest (b3-fold) reduction in the V3-speciﬁc neutralizing activity
of this serum. Linear peptide absorption of V3-speciﬁc antibodies
from CAP206 serum was more effective and resulted in an
approximately 10-fold reduction in the serum neutralizing titer
against HIV-2KR.X7Ccon V3.
Because linear peptides were inefﬁcient at competing with the
HIV-2KR.X7Ccon V3 chimera for serum antibody binding, we hypothe-
sized that the linear peptides might not replicate V3 secondary and
tertiary structures sufﬁciently to serve as effective competing
antigens. We therefore conducted similar absorption experiments
using a chimeric fusion protein containing a rabbit Fc backbone with
the full, disulﬁde bound HIV-1Ccon V3 fused to its amino terminus,
referred to as Fc-V3C FP (A.P. and A.S., unpublished, and Davis et al.,
2009). This reagent was shown in prior studies to compete speciﬁcally
and far more effectively than linear V3 peptides against V3-speciﬁc
mAbs and V3-speciﬁc plasma antibodies from chronically infected
subjects (Davis et al., 2009). In all samples tested, pre-incubationwith
Fc-V3C FP completely removed the serum neutralizing activity,
verifying that the HIV-2KR.X7Ccon V3 chimera is detecting only
antibodies directed at the V3 loop and not reactivity at other HIV-2
epitopes. Neither a scrambled V3 peptide nor a rabbit Fc protein
lacking the V3 loop depleted the neutralizing activities of V3-speciﬁc
mAbs (447-52D and F425 B4e8) or plasma antibodies from infected
subjects, thus conﬁrming that V3 peptides and the rabbit Fc-V3C FP do
not compete nonspeciﬁcally for plasma antibody reactivity (Davis
et al., 2009).
Kinetics of appearance and breadth of V3 reactive antibodies during
natural infection with clade B HIV-1
We performed similar analysis using longitudinal plasma samples
obtained from two patients acutely infected with clade B HIV-1. Data
presented in Fig. 4 and Table 2 show the kinetics of appearance of V3-
speciﬁc antibodies following clade B HIV-1 infection. Plasma samples
obtained from subject WEAU at days 16, 20, 30, 40, and 51 post onset
of symptoms (corresponding to 36, 40, 50, 60, and 71 days after the
estimated date of infection) contained no detectable V3-speciﬁc
antibodies (Fig. 4A). V3-speciﬁc antibody responses were detected by
day 72 post onset of symptoms and increased in titers thereafter,
reaching a maximum IC50 neutralizing titer of 5275 by day 212 against
the clade-matched chimera, HIV-2KR.X7YU2 V3. Similar to our ﬁndings
with the clade C natural infection cohort, cross-clade V3-speciﬁc
neutralizing titers for subjectWEAUwere lower, reaching a maximum
IC50 plasma dilution of 276 against the HIV-2KR.X7Ccon V3 chimera by
day 212 post onset of symptoms. We made similar observations for
subject BORI who was also sampled during acute infection by clade B
HIV-1 (Fig. 4B and Table 2). V3-speciﬁc antibodies capable of
neutralizing the HIV-2KR.X7YU2 V3 chimera were detected in plasma
obtained on day 65 after the onset of symptoms (approximately
79 days after the estimated date of infection) and increased in potency
to an IC50 neutralizing titer of 28,729 by day 556. These antibodies
again demonstrated diminished but readily detectable cross-clade
418 K.L. Davis et al. / Virology 387 (2009) 414–426reactivity with IC50 titers against the HIV-2KR.X7Ccon V3 chimera of
2066 by day 556 post onset of symptoms.
We considered the possibility that within-clade V3 diversity might
limit our ability to detect clade B V3-speciﬁc responses in the earliestplasma specimens since we had used an HIV-2/HIV-1 V3 Env chimera
containing a heterologous B clade V3 sequence from a prototypic
strain HIV-1YU2 (Davis et al., 2009). We therefore constructed three
additional HIV-2KR.X7HIV-1 V3 chimeras each containing the V3 loop
419K.L. Davis et al. / Virology 387 (2009) 414–426autologous to that of virus ampliﬁed from the subjects WEAU
and BORI. The V3 sequences for the HIV-2KR.X7WEAU V3 and HIV-
2KR.X7BORI V3 chimeras are presented in Fig. 1B. Fig. 4A and Table 2
show that for patient WEAU, plasma V3-speciﬁc neutralizing activity
directed at autologous V3 epitopes, measured by the HIV-2KR.X7WEAU
V3 chimera, develops with the same kinetics and potency as
that directed at within-clade heterologous epitopes present on HIV-
2KR.X7YU2 V3, and that the neutralization curves for these viruses are
superimposable. The results were similar for BORI. Two chimeras
containing V3 sequences autologous to HIV-1BORI were used in these
experiments. HIV-2KR.X7BORId6 V3 contains the V3 loop of virus
ampliﬁed on day 6 post onset of symptoms and HIV-2KR.X7BORId556 V3
contains the V3 loop of day 556 virus. Neutralization curves of HIV-
2KR.X7BORId6 V3, HIV-2KR.X7BORId556 V3, and HIV-2KR.X7YU2 V3 by
serial BORI plasmas were again virtually superimposable (Fig. 4B and
Table 2). These results highlight the antigenic conservation of V3 that
exists within clade B HIV-1 and suggest that the earliest V3 Nab
responses in natural infection exhibit substantial heterologous
within-clade cross reactivity.
Titers and breadth of V3 antibodies elicited by vaccination
We next sought to assess the breadth and titers of V3-speciﬁc Nabs
elicited after immunization with two HIV-1 vaccine candidates and
determine to what degree V3 antibodies might contribute to the
neutralizing potency of the sera against a heterologous primary virus,
HIV-1YU2. In the HVTN Protocol 203 vaccine study, participants were
immunized with a canarypox HIV vaccine, ALVAC-HIV vCP1452, that
encodes the HIV-1MN gp120, full HIV-1LAI Gag protein, a portion of the
pol gene, and multiple CTL epitopes located in nef and pol. ALVAC-HIV
vCP1452, or a sham control, was administered by intramuscular
injection to all participants and responses were boosted in a subset of
individuals with the recombinant AIDSVAX™ B/B gp120 subunit
immunogen composed of the gp120 proteins from HIV-1MN and HIV-
1GNE8 (both derived from subtype B viruses). A detailed description of
the HVTN Protocol 203 vaccine cohort and immunization schedule has
been published (Russell et al., 2007).
Our analysis represented a pilot study designed to test if V3-
speciﬁc antibodies could be detected in vaccinees. Power calculations
indicated that ten-fold differences in median IC50 titers, if present,
could be detected between groups of ﬁve subjects given the precision
and reproducibility of the TZM-bl neutralization assay (Monteﬁori,
2004; Wei et al., 2003). The analyses were thus conducted on a subset
of HVTN Protocol 203 study participants that included ﬁve subjects in
each of three immunization groups: those receiving four immuniza-
tions with the ALVAC-HIV vCP1452 immunogen alone, those receiving
four immunizations with the ALVAC-HIV vCP1452 immunogen plus
AIDSVAX protein boosts, and those receiving four immunizations with
a placebo immunogen. We tested sera from these patients for V3-
speciﬁc neutralizing activity against an HIV-2/HIV-1 V3 chimera
containing the autologous HIV-1MN V3 loop (HIV-2KR.X7MN V3) andFig. 2. Kinetics of development and breadth of V3-speciﬁc antibodies during acute
clade C HIV-1 infection. (A) HIV-2KR.X7HIV-1 V3 chimeras and control viruses were
tested for neutralization susceptibility to sera obtained from fourteen patients acutely
infected with clade C HIV-1 (CAPRISA cohort) (Gray et al., 2007; Moore et al., 2008).
Virus entry was measured by luciferase production in TZM-bl reporter cells 48 h after
infection and normalized to luciferase expression in the absence of serum.
Neutralization of HIV-2KR.X7Ccon V3 is represented by blue lines. Neutralization of
HIV-2KR.X7YU2 V3 is shown in green. Neutralization of control viruses, HIV-2KR.X4 and
HIV-2KR.X7, by serum drawn at the last time point for each patient, is shown in gray.
IC50 neutralization values are presented in Table 1. (B) Reciprocal IC50 neutralization
titers for CAPRISA sera against HIV-2KR.X7Ccon V3 (blue), HIV-2KR.X7YU2 V3 (green),
autologous clade C HIV-1 (black), and the heterologous clade C HIV-1Du151 (gray), are
plotted. Sera for these studies were obtained at approximately 5 months post infection
for each patient. Median values are marked with a horizontal line. IC50 values for all
sera tested against control HIV-2 viruses were b1:20. Comparisons that show
statistical signiﬁcance are indicated.
Fig. 3. Epitope speciﬁcity of neutralization of HIV-2KR.X7Ccon V3 chimeras by clade C sera. Neutralization of the HIV-2KR.X7Ccon V3 chimera by sera obtained from CAP084, CAP088,
CAP206, and CAP239 is inhibited modestly by full-length linear V3 peptides matching the autologous sequence (dashed line, open symbol) and completely by the Fc-V3C fusion
protein (FP; dashed line, closed symbol). Media only controls (solid line, open symbol) show serum neutralization in the absence of competing peptide or Fc-V3C FP. Neither a
scrambled V3 peptide nor a rabbit Fc protein lacking the V3 loop depleted the neutralizing activities of clade C plasma antibodies, thus conﬁrming that V3 peptides and the rabbit Fc-
V3C FP do not compete nonspeciﬁcally for plasma antibody reactivity (data not shown and Davis et al., 2009).
Fig. 4. Kinetics of development and breadth of V3-speciﬁc antibodies during acute clade B HIV-1 infection. HIV-2KR.X7HIV-1 V3 chimeras and control viruses were tested for
neutralization sensitivity to plasma obtained from two patients acutely infected with clade B HIV-1. Neutralization of HIV-2KR.X7YU2 V3 (green) and HIV-2KR.X7Ccon V3 (blue) by
plasma samples from each time point is shown. To assess the effects of within-clade V3 diversity on the detection of V3-speciﬁc antibodies by the HIV-2KR.X7HIV-1 V3 chimeras, we
constructed three additional chimeras containing V3 sequences matching those of patients WEAU and BORI. (A) Neutralization of HIV-2KR.X7WEAU V3 by autologous plasmas is
shown in black. (B) Neutralization of HIV-2KR.X7HIV-1 V3 chimeras containing the V3 sequence of HIV-1BORI from day 6 and day 556 post onset of symptoms by autologous plasmas is
shown in black (solid lines: HIV-2KR.X7BORId6 V3; dashed lines: HIV-2KR.X7BORId556 V3). IC50 neutralization values are presented in Table 2.
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Table 2
Neutralization titers of clade B plasmas against HIV-2, HIV-1, and HIV-2/HIV-1 V3 chimeras.
Plasma Daysa Reciprocal IC50
HIV-2KR.X4 HIV-2KR.X7 HIV-2KR.X7
YU2 V3
HIV-2KR.X7
Ccon V3
HIV-2KR.X7
WEAU V3
HIV-2KR.X7
BORId6 V3
HIV-2KR.X7
BORId556 V3
WEAU 16 b100 b100 b100 b100 b100 ND ND
20 b100 b100 b100 b100 b100 ND ND
30 b100 b100 b100 b100 b100 ND ND
40 b100 b100 b100 b100 b100 ND ND
51 b100 b100 b100 b100 b100 ND ND
72 b100 b100 292 b100 216 ND ND
136 b100 b100 1179 114 1310 ND ND
212 b100 b100 5275 276 4097 ND ND
391 b100 b100 4061 152 3119 ND ND
619 b100 b100 2978 125 1345 ND ND
BORI 9 b100 b100 b100 b100 NDb b100 b100
65 b100 b100 1790 150 ND 756 756
218 b100 b100 11282 1145 ND 9038 6868
556 b100 b100 28729 2066 ND 22605 20586
a Days post onset of symptoms.
b ND: Not done.
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2KR.X7YU2 V3 and HIV-2KR.X7Ccon V3. The control viruses HIV-2KR.X4
and HIV-2KR.X7 were also tested with all sera. Results are summarized
in Fig. 5 and Table 3. Fig. 5A shows that all subjects receiving the
ALVAC-HIV vCP1452 immunogen developedmoderately high titer V3-
speciﬁc antibodies. These antibodies recognized the autologous MN
V3 loop most efﬁciently, the heterologous clade B YU2 V3 loop
intermediately, and the cross-clade subtype C V3 sequence least well.
For example, subject ALVAC1, who received four immunizations with
the ALVAC-HIV vCP1452 immunogen alone, developed V3-speciﬁc
antibodies that neutralized the autologous HIV-2KR.X7MN V3 chimera
at a reciprocal IC50 serum dilution of 906, the heterologous HIV-
2KR.X7YU2 V3 chimera at a reciprocal IC50 of 136, and the cross-clade
heterologous HIV-2KR.X7Ccon V3 chimera at a titer of 111. Fig. 5D
shows this to be a general feature of the V3 response to the ALVAC-HIV
vCP1452 immunogen. Median reciprocal IC50 neutralization titers for
all ﬁve subjects were 1,160 (range, 906 to 1745) against HIV-2KR.X7MN
V3 and less against HIV-2KR.X7YU2 V3 (IC50=156; range, 68 to 802;
p=0.0006) and HIV-2KR.X7Ccon V3 (IC50=142; range, 23 to 402;
p=0.0009). These data demonstrate that vaccination with the
ALVAC-HIV vCP1452 immunogen alone elicits V3-speciﬁc antibodies
of substantial titer but limited breadth.
The V3 antibody responses elicited by the ALVAC-HIV vCP1452/
AIDSVAX immunization schedule, which included an Env protein
boost, were more substantial and showed much greater breadth of
V3 reactivity (Fig. 5B). All ﬁve subjects who received four
immunizations with the ALVAC-HIV vCP1452 immunogen plus
gp120 protein boosts developed high titer V3-speciﬁc antibodies
that neutralized the HIV-2KR.X7MN V3, HIV-2KR.X7YU2 V3, and HIV-
2KR.X7Ccon V3 chimeras at equivalent titers. For these subjects, the
median reciprocal IC50 serum dilutions were 1527 against HIV-2KR.
X7MN V3 (range, 710 to 3078), 3137 against HIV-2KR.X7YU2 V3
(range, 883 to 3338), and 1997 against HIV-2KR.X7Ccon V3 (range,
497 to 2307) (Fig. 5D). The control viruses, HIV-2KR.X4 and HIV-
2KR.X7, were not neutralized by sera from vaccines immunized with
either ALVAC-HIV vCP1452 or ALVAC-HIV vCP1452/AIDSVAX sera,
indicating that the observed neutralizing activities in the sera
against the HIV-2KR.X7HIV-1 V3 chimeras were directed at HIV-1
V3 epitopes. Pre-immune sera from ALVAC-HIV vCP1452 and
ALVAC-HIV vCP1452 plus AIDSVAX study participants (Figs. 5A–
C), and from those receiving a placebo immunogen (Fig. 5C), failed
to neutralize the HIV-2KR.X7HIV-1 V3 chimeras or the control
viruses.
We also assessed the ability of vaccinee sera to neutralize
autologous and heterologous HIV-1 viruses. Autologous neutralization
was measured against the laboratory-adapted, neutralization sensi-tive clade B HIV-1MN virus, a component of the vaccine formulation for
both the ALVAC-HIV vCP1452 and ALVAC-HIV vCP1452/AIDSVAX
groups. Serum neutralization of HIV-1YU2 served as a measure of
heterologous neutralization for these experiments. Fig. 5D sum-
marizes the results. Sera from individuals receiving the ALVAC-HIV
vCP1452 immunogen alone displayed weak neutralizing activity
against HIV-1MN (reciprocal IC50 serum dilution=56; range, 56 to
100) at titers that were signiﬁcantly lower than those observed for the
HIV-2KR.X7MN V3 chimera (p=0.0016). None of the subjects
immunized with the ALVAC-HIV vCP1452 vaccine developed Nabs
against the heterologous HIV-1 clade B strain, HIV-1YU2. Sera from
individuals receiving the ALVAC-HIV vCP1452 vaccine plus AIDSVAX
rgp120 protein boost neutralized the autologous HIV-1 strain, HIV-
1MN, at slightly higher titers (median reciprocal IC50=100; range, 91
to 139), but again these titers were signiﬁcantly lower than those
measured against the HIV-2KR.X7MN V3 chimera (p=0.0148), the
HIV-2KR.X7YU2 V3 chimera (p=0.0107), and the HIV-2KR.X7Ccon V3
chimera (p=0.0184). None of the vaccinee sera, which potently
neutralized the three HIV-2/HIV-1 V3 chimeras, displayed detectable
neutralization against the primary HIV-1YU2 virus (IC50b20; pb0.05
for each).
Discussion
Deciphering the speciﬁcities of the earliest Nabs that arise during
natural HIV-1 infection and in response to vaccination and deﬁning
their contributions to constraints on HIV-1 replication and evolution
can contribute to our understanding of HIV-1 natural history, and
eventually, to effective vaccination design. Previous studies of the
antibody response directed to HIV-1 V3 in chronically infected
humans and in vaccinated animals demonstrated the exceptional
immunogenicity of V3 peptide sequences in vivo (Davis et al., 2009;
Goudsmit et al., 1988; Javaherian et al., 1989; Nara et al., 1990; Palker
et al., 1988; Profy et al., 1990; Rusche et al., 1988; Wu et al., 2006;
Zolla-Pazner et al., 2008), but the kinetics of appearance of V3-speciﬁc
Nabs were far less well characterized (Goudsmit et al., 1988; Moore et
al., 1994; Tomaras et al., 2008). In addition, the breadth of reactivity of
early V3 Nab responses and their contributions to neutralization of
primary virus strains in acute infection or following vaccination had
not been clearly elucidated. In the present study, we employed a panel
of HIV-2/HIV-1 V3 chimeras to quantify V3-speciﬁc Nabs in sera from
individuals acutely infected with clade C or clade B HIV-1 and from
subjects vaccinated with two immunogens derived from clade B HIV-1
strains. We found that during acute infection with clade C or clade B
HIV-1, patients rapidly develop V3-speciﬁc antibodies that affect
potent neutralization of the HIV-2KR.X7HIV-1 V3 chimeras. As early as
Fig. 5. Breadth of V3-speciﬁc antibodies elicited by vaccination with HIV-1 immunogens. Sera from individuals immunized with ALVAC-HIV vCP1452 vaccine (A), ALVAC-HIV
vCP1452 and AIDSVAX rgp120 B/B protein (B), or placebo (C) were tested for neutralizing activity against the HIV-2KR.X7HIV-1 V3 chimeras and control viruses. Virus neutralization
by paired pre-immune sera is shown in the left panels. Neutralization of HIV-2KR.X7MN V3, containing the V3 loop autologous to that of the vaccine immunogens, is shown in red.
Neutralization of HIV-2KR.X7YU2 V3 and HIV-2KR.X7Ccon V3 is shown in green and blue, respectively. Neutralization of the control virus HIV-2KR.X7 is shown in gray. IC50 neutralizing
titers are reported in Table 3. (D) Reciprocal IC50 neutralization titers for vaccinee sera against HIV-2KR.X7MN V3 (red), HIV-2KR.X7YU2 V3 (green), HIV-2KR.X7Ccon V3 (blue),
autologous clade B virus (HIV-1MN; black), and the heterologous clade B virus (HIV-1YU2; gray), are plotted. Median values are marked with a horizontal line. IC50 values for all sera
tested against control HIV-2 viruses was b1:20. Comparisons that show statistical signiﬁcance are indicated.
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Table 3
Neutralization titers of vaccine sera against HIV-2, HIV-1, and HIV-2/HIV-1 V3 chimeras.
Subject Reciprocal IC50
HIV-2KR.X4 HIV-2KR.X7 HIV-2KR.X7
MN V3
HIV-2KR.X7
YU2 V3
HIV-2KR.X7
Ccon V3
Autologous
(HIV-1MN)
Heterologous
(HIV-1YU2)
ALVAC
1 b20 b20 906 136 111 56 b20
2 b20 b20 1160 68 246 56 b20
3 b20 b20 968 156 142 77 b20
4 b20 b20 1745 802 402 56 b20
5 b20 b20 1307 714 23 100 b20
ALVAC/AIDSVAX
1 b20 b20 710 883 497 100 b20
2 b20 b20 1527 3137 2307 139 b20
3 b20 b20 3078 1478 733 91 b20
4 b20 b20 2121 3338 1977 91 b20
5 b20 b20 1388 3295 1993 237 b20
Placebo
1 b20 b20 b20 b20 b20 b20 b20
2 b20 b20 b20 b20 b20 b20 b20
3 b20 b20 b20 b20 b20 b20 b20
4 b20 b20 b20 b20 b20 b20 b20
5 b20 NDa b20 b20 b20 b20 b20
a ND: Not done.
423K.L. Davis et al. / Virology 387 (2009) 414–426approximately 5 wpi, sera from 12 of 14 (86%) clade C HIV-1 infected
subjects (CAPRISA cohort) neutralized the clade-matched V3 chimera,
HIV-2KR.X7Ccon V3, at a median reciprocal IC50 serum dilution of 706
(Fig. 2A and Table 1). All of these subjects exhibited V3-speciﬁc
neutralizing activities by 12wpi, whichwas prior to or coincident with
the development of autologous Nabs for these individuals (Table 1).
By 5 months post infection, clade C infected subjects developed V3-
speciﬁc antibodies that reached a median IC50 neutralizing titer of
8127. These latter results are similar to our ﬁndings in a previous study
of plasmas from individuals chronically infected with clade C HIV-1 in
which we found that neutralizing titers against HIV-2KR.X7Ccon V3
occurred at a median reciprocal IC50 plasma dilution of 8488 (Davis et
al., 2009). Also in agreement with our ﬁndings in chronically infected
subjects, we found that the anti-V3 reactivities detected in subjects
acutely by clade C virus patients could neutralize the HIV-2KR.X7YU2
V3 chimera, containing a clade B HIV-1 V3 loop. These cross-clade V3-
speciﬁc neutralizing titers were detected at enrollment and increased
as infection progressed.
A comparison of the kinetics of appearance of V3-speciﬁc Nabs
with those targeting CD4i epitopes, the MPER, or other epitopes that
mediate autologous neutralization (Davis et al., 2009; Gray et al.,
2007; Moore et al., 2008) demonstrated that anti-V3 Nabs are the ﬁrst
of this group to appear during acute clade C HIV-1 infection. For
subjects in the CAPRISA natural infection cohort, antibodies directed
at CD4i epitopes, as measured by an HIV-2 virus pre-triggered with
sub-maximal concentrations of soluble CD4 (Decker et al., 2005),
were previously reported to be present at approximately 5 wpi in only
5 of 14 (36%) individuals, and then, at titers that ranged from b20 to
823 (reciprocal IC50 serum dilution). At 5 months post infection, CD4i
titers in these subjects had increased to a median reciprocal IC50
neutralizing titer of 38 (range, b20 to 631) andwere detected in only 8
of 14 (57%) patients (Gray et al., 2007). Antibodies reactive with the
HIV-1 MPER were found in even fewer subjects, with only 3 of 14
individuals exhibiting IC50 titers of between 28 and 51 during this
study period (Gray et al., 2007). Additionally, the kinetics of
appearance of autologous Nabs was delayed compared with the V3-
speciﬁc antibody response. Upon enrollment into the CAPRISA cohort,
none of the acutely infected subjects had detectable Nab titers against
autologous enrollment virus (Table 1) and subsequent autologous Nab
responses reached a median titer of only 261 by 5 months post
infection (Fig. 2B and Table 1). A comparison with V3-speciﬁc
antibodies, which reached median titers of N8000 by 5 monthspost-infection and were present in all individuals, demonstrates that
antibodies targeting the V3 loop developed ﬁrst and to higher titers
compared with antibodies of CD4i, MPER, or strain-speciﬁc (auto-
logous) speciﬁcities. The discordance between the kinetics of
appearance and titers of V3 Nabs versus autologous strain-speciﬁc
Nabs, and the breadth of reactivity displayed by V3 Nabs versus
autologous antibodies, demonstrate that V3-speciﬁc antibodies con-
tribute little if anything to the neutralization of autologous virus
during acute, early, or chronic clade C HIV-1 infection. Our ﬁndings
thus corroborate observations published by Moore et al. (2008) in
which the autologous Nab responses were mapped to epitopes
distinct from the HIV-1 V3.
Our analyses of two patients acutely infected with clade B HIV-1
indicated that broadly reactiveV3-speciﬁc antibodies are elicited to high
titers during acute clade B infection (Fig. 4 and Table 2). The data for the
clade B HIV-1 infected subjects support our conclusions that V3-speciﬁc
antibodies do not contribute to autologous or heterologous neutraliza-
tion. For example, plasma drawn from patient BORI on day 218 post
onset of symptoms contained V3-speciﬁc antibodies that neutralized
theHIV-2KR.X7YU2V3 chimera at a reciprocal IC50 titer of N11,000 (Table
2) but this same plasma failed to neutralize the primary HIV-1YU2 strain
at a 1:10 dilution (Wei et al., 2003). Additionally, HIV-2KR.X7HIV-1 V3
chimeras containing HIV-1BORI V3 sequences from day 6 and day 556
post onset of symptoms were constructed (Fig. 1B) and tested against
the longitudinal BORI plasmas. We again detected high titer V3-speciﬁc
reactivity in day 218 plasma (reciprocal IC50 plasma dilutions of 9038
and 6868 for HIV-2KR.X7BORId6 and HIV-2KR.X7BORId556 chimeras,
respectively; Fig. 4 and Table 2). This potent V3-speciﬁc reactivity was
not reﬂected in the autologous neutralization titers when tested against
primary HIV-1BORI virus (Wei et al., 2003). In addition, previous studies
fromour laboratory have shown that theprimaryHIV-1BORI Env ishighly
resistant to two broadly reactive V3mAbs, 447–52D and F425 B4e8, and
to V3-speciﬁc antibodies in plasmas from chronically infected patients,
while the HIV-2KR.X7BORId6 V3 chimera, which presents the identical V3
loop, shows remarkable sensitivity to thesemAbs andpolyclonal plasma
antibodies (Davis et al., 2009; Keele et al., 2008).
The ﬁnding that a broadly reactive high titer V3-speciﬁc antibody
response is characteristic of acute HIV-1 infection prompted us to
evaluate the speciﬁcities of the humoral response to clade B HIV-1
vaccine immunogens. Fig. 5D demonstrates that subjects receiving
the ALVAC-HIV vCP1452 immunogen developed potent V3-speciﬁc
Nabs against the HIV-2KR.X7MN V3 chimera, which contains the V3
424 K.L. Davis et al. / Virology 387 (2009) 414–426sequence identical to that included in the vaccine preparation, and
that these V3-speciﬁc responses were moderately cross reactive at
heterologous V3 epitopes as measured by the HIV-2KR.X7YU2 V3
(clade B) and HIV-2KR.X7Ccon V3 (clade C) chimeras. Addition of the
AIDSVAX B/B monomeric gp120 protein boost to the immunization
protocol resulted in equivalent neutralization titers against HIV-2KR.
X7MN V3, but substantially broadened neutralization against the
chimeras containing heterologous clade-matched and cross-clade V3
epitopes. Median reciprocal IC50 neutralizing titers for these sera
were 1527 against HIV-2KR.X7MN V3, 3137 against HIV-2KR.X7YU2 V3,
and 1997 against HIV-2KR.X7Ccon V3. In a previous study, we
determined CD4i Nab titers in these same vaccines (Decker et al.,
2005). We found that 3 of 5 individuals receiving the ALVAC-HIV
vCP1452 based immunogen had detectable CD4i Nabs at a median
titer of 23 (range, b20 to 53). All ﬁve subjects receiving the ALVAC-
HIV vCP1452/AIDSVAX vaccine formulation developed detectable
CD4i antibodies at a median reciprocal IC50 neutralizing titer of 179
(range, 53 to 357), signiﬁcantly lower than the V3-speciﬁc titers
measured for these individuals. Thus, we could conclude in this
limited number of vaccinees that V3 was more immunogenic than
CD4i epitopes, similar to our ﬁndings in individuals with acute and
early HIV-1 infection.
Analysis of neutralizing activity against autologous and hetero-
logous HIV-1 strains by vaccinee sera also demonstrated similarities
to the antibody responses elicited during natural HIV-1 infection.
Sera obtained from subjects receiving both the ALVAC-HIV vCP1452
and ALVAC vCP1452/AIDSVAX vaccine formulations exhibited potent
neutralization against HIV-2KR.X7MN V3, reaching titers N1000. These
same immune sera, however, neutralized the autologous HIV-1MN
isolate at titers at least 10-fold lower, demonstrating that the
neutralizing potency of V3-speciﬁc antibodies is signiﬁcantly
reduced when the V3 is presented in its native HIV-1 Env. This
result was corroborated by an analysis of a second virus targeted by
sera from subjects who received the ALVAC-HIV vCP1452/AIDSVAX
immunogen. Sera from these vaccinees contained Nabs against the
HIV-2KR.X7YU2 V3 chimera with a median reciprocal IC50 neutralizing
titer of N3000, but they were ineffective at neutralizing the primary
HIV-1YU2 virus containing an identical V3 sequence at titers of 1:20.
These ﬁndings demonstrate that while these HIV-1 Env immunogens
readily elicited V3 speciﬁc antibodies with broad neutralizing
potential, the potency of these antibodies against primary viruses
is low.
Together, these data highlight important similarities in the V3-
speciﬁc antibody responses elicited during acute and chronic HIV-1
infection and following vaccination with HIV-1 immunogens. In all
cases, V3-speciﬁc antibodies were elicited early and to high titers.
These V3 reactive antibodies were of substantial breadth, capable of
mediating neutralization against within-clade and cross-clade V3
epitopes. However, these antibodies exhibited reduced neutralizing
potency against autologous HIV-1 isolates and failed to neutralize
typical primary HIV-1 strains at all. These observations highlight the
exceptional V3 shielding that is characteristic of primary HIV-1
viruses (Davis et al., 2009; Krachmarov et al., 2005, 2006; Pinter,
2007), which effectively limits the contributions of V3-speciﬁc
antibodies to virus neutralization in acute and chronic HIV-1 infection
and subsequent to vaccination with HIV-1 immunogens. These data
contribute to a growing body of evidence showing that while HIV-1
V3 is highly immunogenic and elicits antibodies that recognize V3
epitopes that are conserved among diverse HIV-1 strains (Davis et al.,
2009; Goudsmit et al., 1988; Krachmarov et al., 2005; Wu et al., 2006;
Zolla-Pazner et al., 2008), such antibodies are generally poor effectors
of neutralization of primary viruses due to concealment of V3
epitopes on the native HIV-1 Env trimer (Davis et al., 2009;
Krachmarov et al., 2005, 2006). If V3 directed antibodies are to be a
component of an effective HIV-1 vaccine, such shielding of V3must be
overcome.Materials and methods
Study subjects
Fourteen women with acute HIV-1 clade C infection were studied.
These individuals were part of the CAPRISA cohort (Gray et al., 2007;
Moore et al., 2008) of high risk sex workers in Durban, South Africa,
who had been counseled regarding safe sex practices and followed
prospectively by monthly testing for plasma HIV-1 RNA and
antibodies for incident HIV-1 infection. The timing of HIV-1 infection
was estimated by CAPRISA investigators to be the midpoint between
the last HIV-1 antibody negative sample and the ﬁrst antibody
positive sample or 14 days before the individual was found to be
plasma HIV-1 vRNA positive and antibody negative. This method for
estimating the date of virus infection may underestimate the actual
duration between virus transmission and sampling in a substantial
fraction of newly infected individuals and thus comparisons of the
timing of antibody responses between different studies must be done
with this caveat in mind. Two subjects with acute HIV-1 clade B
infection were identiﬁed based on symptomatic primary infection
(Wei et al., 2003) at the University of Alabama at Birmingham.
Following the diagnosis of acute HIV-1 infection, all 16 subjects had
serial phlebotomies on a weekly, monthly, and quarterly basis for the
collection and cryopreservation of serum, plasma and peripheral
blood mononuclear cells. None of the HIV-1 infected subjects received
antiretroviral therapy during the course of follow-up described in this
study. Samples from ﬁfteen HIV-1 uninfected study participants in
HVTN Protocol 203 study were obtained from the NIAID HIV Vaccine
Trials Network (http://www.hvtn.org/). All study protocols received
Institutional Review Board approval and study subjects provided
informed consent.
Molecular cloning and mutagenesis
The construction of pHIV-2KR.X4, pHIV-2KR.X7, and pHIV-2KR.X7HIV-
1 V3 chimeras containing V3 sequences from HIV-1MN (Accession
number: M17449, Gurgo et al., 1988), HIV-1YU2 (Accession number:
M93258, Li et al., 1992) or HIV-1Ccon (Los Alamos Sequence Database:
http://www.hiv.lanl.gov/) has been described (Davis et al., 2009).
Substitution of V3 sequences from HIV-1WEAU (Accession number:
AY223750, Wei et al., 2003), HIV-1BORI_d6 (Accession number:
AY223720, Keele et al., 2008; Wei et al., 2003) and HIV-1BORI_d556
(Accession number: AY223732, Wei et al., 2003) was completed using
a modiﬁed version of the QuikChange™ Site-Directed Mutagenesis
protocol (Stratagene, La Jolla, CA). 5′ phosphorylated (Phos) primers
were designed to anneal to the HIV-2KR backbone immediately
ﬂanking the HIV-2KR.X7 V3 region and contained the desired HIV-1
V3 substitutions as follows: HIV-1WEAU V3: GTACTTTATACAACAGGA-
GAAATAATAGGAGATATAAGACGAGCACATTGCTGGTTCGGAGGT-
GATTGG, [Phos] TCTCCCTGGTCCTAAAGTTATCCCTTTTCTTG-
TATTGTTGTTGGGTCTTATACAATGCATTGTGAG; HIV-1BORI_d6: ACATTT-
TATACAACAGGAGACATAATAGGAGATATAAGGCAGGCA -
TATTGCTGGTTCGGAGGTGATTGG, [Phos] TCTCCCTGGTCCTATAT-
GTATACTTTTTCTTGTATTGTTGTTGGGTCTTGTACAATGCATTGTGAG;
HIV-1BORI_d556: ACATTTTATACAACAGGAGACATAATAGGAAATATAAGG-
CAAGCACATTGCTGGTTCGGAGGTGATTGG, [Phos] TCTCCCTGGTCCTA-
TATGTATACCTTTTCTTGTATTGTTGTTGGGTCTTGTACAATGCATTGTGAG
(Operon Biotechnologies, Inc., Huntsville, AL). Fifteen pmol of each
primer and 100 ng of template DNA [pGEM subclone containing a
1.2 kb Env fragment of pHIV-2KR.X7MN V3(Davis et al., 2009)] were
used for each PCR mutagenesis reaction. PCR conditions were as
follows: 95°C for 1 min (1 cycle); 95°C for 50 s, 50°C for 50 s, 68°C for
6 min (18 cycles); 68°C for 7 min (1 cycle). PCR products were
digested with 10 U of DpnI (New England Biolabs; Ipswich, MA) at
37°C for 1 h to cleave template DNA and heat inactivated at 72°C for
30 min. Ampliﬁcation products were ligated to yield a chimeric env
425K.L. Davis et al. / Virology 387 (2009) 414–426construct with appropriate V3 substitutions and subsequently cloned
into the full-length pHIV-2KR.X7 backbone using the XhoI and XmaI
restriction sequences. Plasmid DNA was transformed into XL2-Blue
MRF' Ultracompetent cells (Stratagene, La Jolla, CA), plated on LB agar
plates supplemented with 5 μg/ml kanamycin and cultured overnight
at 30°C. Single colonies were selected and grown overnight in liquid
LB broth containing 5 μg/ml kanamycin at 30°C with 225 rpm shaking
followed by plasmid isolation. Eachmolecular clone was conﬁrmed by
nucleotide sequencing.
Virus stocks
3×106 293T cells were seeded into 10 cm2 tissue culture dishes
and cultured overnight in complete Dulbecco's modiﬁed Eagle
medium (DMEM; Gibco/Invitrogen, Carlsbad, CA) supplemented
with 10% FBS and 1% PS (D10 media) at 37°C with 5% CO2. The
following day, 6 μg proviral DNA was transfected into 293T cells using
Fugene-6 (Roche Applied Science, Indianapolis, IN) as speciﬁed by the
manufacturer and cultured in D10 media at 37°C for 48 h. Super-
natants containing infectious virus were harvested, cleared of cellular
debris by low-speed centrifugation, and used directly or stored at
−80°C for future use.
Virus titration
1×104 TZM-bl reporter cells per well were seeded in D10 media
and cultured in 96-well tissue culture plates (BD Falcon, Franklin
Lakes, NJ) overnight at 37°C with 5% CO2. The following day, D10
media was removed from the cell monolayers and replaced with 50 μl
DMEM, 6% FBS, 1% PS (D6 media) containing DEAE-Dextran hydro-
chloride at 80 μg/ml (2× ﬁnal concentration). Serial ﬁve-fold dilutions
of virus stock were prepared in D10 media. Fifty μl virus stock dilution
was then transferred to the TZM-bl reporter cells (catalog #8129; NIH
AIDS Research and Reference Reagent Program) bringing the ﬁnal
volume to 100 μl and ﬁnal DEAE-Dextran concentration to 40 μg/ml.
Cells were incubated with virus for 48 h at 37°C, lysed, and analyzed
for luciferase production using the Luciferase Assay System (Promega,
Madison, WI). Future neutralization experiments were performed
using approximately 1×105 RLU/well (96-well format) of virus stock.
Neutralization assays
For these studies, 1×104 TZM-bl cells per well were seeded into
96-well tissue culture plates and cultured overnight in D10 media. Six
ﬁve-fold serial serum dilutionswere prepared in D6media. Virus 293T
stock supernatants were prepared as described previously and diluted
to approximately 1×105 RLU/well in D10 media containing 80 μg/ml
DEAE-Dextran hydrochloride. Equal parts serum and virus dilutions
were then combined and incubated at 37°C for 1 h. Media was
removed from the TZM-bl cells, 100 μl of the virus/serummixture was
applied to the cells and incubated for an additional 48 h at 37°C with
5% CO2. Control wells included a virus-only control (no serum) and a
media-only control (no serum, no virus). Luciferase expression was
quantiﬁed according to the Luciferase Assay System protocol
(Promega, Madison, WI). All wells except the starting serum dilution
were supplemented with 2% (for a 1:50 starting dilution) or 10% (for a
1:10 starting dilution) normal human serum.
Peptide and fusion protein competition assays
Linear peptides comprising full-length V3 sequences (33-mer)
from autologous CAPRISA viruses were purchased from NMI peptides
(Reutlingen, Germany) and supplied by the NICD (Moore et al., 2008).
Inhibition experiments were performed as described above for serum
neutralization assays, except that serum dilutions were preincubated
with peptide (ﬁnal concentration, 50 μg/ml) for 30 min at 37°C priorto incubation with virus. Fusion protein (Fc-V3C FP) consisted of a
rabbit IgG Fc molecule with a complete HIV-1Ccon V3 loop linked to its
N-terminus (A.P. and A.S., unpublished, and Davis et al., 2009). Fusion
protein inhibition studies were performed as described above for the
peptide inhibition assays with Fc-V3C FP at a ﬁnal concentration of
10 μg/ml. Peptide and Fc-V3 FP concentrations were kept constant in
all wells including control wells. Controls included scrambled V3
peptide and rabbit IgG Fc alone or rabbit IgG Fc-V3 containing a Gly-
Ala-Gly linker to replace the 19 amino acids of the V3 tip residues [Fc-
V3p8027 (Davis et al., 2009)].
Statistical analyses
Median reciprocal IC50 neutralization titers were compared by the
Wilcoxon Rank Sum test using the SAS version 9.1 software package. A
p-value of 0.05 was considered signiﬁcant for these studies.
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